Clinical Trial

Remibrutinib in Real-world Clinical Practice

Study acronym: REASSERT
Recruiting
View on ClinicalTrials.gov →
Summary
Prospective, multi-country, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-13; most recent amendment 2026-04-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-06
Trial Details
NCT Number NCT07358364
Lead Sponsor Novartis Pharmaceuticals
Conditions Chronic Spontaneous Urticaria
Enrollment 3,280 participants
Start Date 2026-02-02
Primary Completion 2031-10-30 (estimated)
Study Completion 2031-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-16